Dayvigo (Lemborexant) Patent Expiration, LOE Window & CMS Spending
Dayvigo (Lemborexant) by Eisai: FDA Orange Book core substance LOE 2031-09-20 (last listed 2035-10-21), 0 AB generics, $26.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eisai |
| FDA Application & Pathway | N212028 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-09-20 |
| Last Listed Patent or Exclusivity Date | 2035-10-21 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $26.4M |
| 2024 Medicare Part D Spend | $21.0M |
| 2024 Medicaid Spend | $5.4M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 19.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.